Clinical Trial

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called itraconazole.
Protocol Amendment History 3 changes
critical Trial completed 2026-06-26
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-27
critical Recruitment opened 2026-05-01
Trial Details
NCT Number NCT07548606
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 14 participants
Start Date 2026-05-11
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-25